BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohammadkhani A, Fragale JE, Pantazis CB, Bowrey HE, James MH, Aston-Jones G. Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil. J Neurosci 2019;39:9831-40. [PMID: 31641055 DOI: 10.1523/JNEUROSCI.0255-19.2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. Medicine in Drug Discovery 2020;8:100059. [DOI: 10.1016/j.medidd.2020.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wiskerke J, James MH, Aston-Jones G. The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task. Brain Res 2020;1731:146222. [PMID: 31002819 DOI: 10.1016/j.brainres.2019.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
3 Venniro M, Banks ML, Heilig M, Epstein DH, Shaham Y. Improving translation of animal models of addiction and relapse by reverse translation. Nat Rev Neurosci 2020;21:625-43. [PMID: 33024318 DOI: 10.1038/s41583-020-0378-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
4 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kupchik YM, Prasad AA. Ventral pallidum cellular and pathway specificity in drug seeking. Neurosci Biobehav Rev 2021;131:373-86. [PMID: 34562544 DOI: 10.1016/j.neubiorev.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Elam HB, Perez SM, Donegan JJ, Lodge DJ. Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 2021;11:114. [PMID: 33558469 DOI: 10.1038/s41398-021-01235-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Swain Y, Waller NG, Gewirtz JC, Harris AC. Individual Differences in Different Measures of Opioid Self-Administration in Rats Are Accounted for by a Single Latent Variable. Front Psychiatry 2021;12:712163. [PMID: 34557118 DOI: 10.3389/fpsyt.2021.712163] [Reference Citation Analysis]
8 Heinsbroek JA, Giannotti G, Mandel MR, Josey M, Aston-Jones G, James MH, Peters J. A common limiter circuit for opioid choice and relapse identified in a rodent addiction model. Nat Commun 2021;12:4788. [PMID: 34373454 DOI: 10.1038/s41467-021-25080-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Poisson CL, Engel L, Saunders BT. Dopamine Circuit Mechanisms of Addiction-Like Behaviors. Front Neural Circuits 2021;15:752420. [PMID: 34858143 DOI: 10.3389/fncir.2021.752420] [Reference Citation Analysis]
10 James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res 2020;1731:146665. [PMID: 31930996 DOI: 10.1016/j.brainres.2020.146665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
11 Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addict Biol 2021;26:e12946. [PMID: 32798290 DOI: 10.1111/adb.12946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
12 Katzman MA, Katzman MP. Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone. Brain Sciences 2022;12:150. [DOI: 10.3390/brainsci12020150] [Reference Citation Analysis]
13 Pantazis CB, James MH, O'Connor S, Shin N, Aston-Jones G. Orexin-1 receptor signaling in ventral tegmental area mediates cue-driven demand for cocaine. Neuropsychopharmacology 2021. [PMID: 34635803 DOI: 10.1038/s41386-021-01173-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vaseghi S, Zarrabian S, Haghparast A. Reviewing the role of the orexinergic system and stressors in modulating mood and reward-related behaviors. Neurosci Biobehav Rev 2021;133:104516. [PMID: 34973302 DOI: 10.1016/j.neubiorev.2021.104516] [Reference Citation Analysis]
15 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Reference Citation Analysis]